Enter your terms above and click the 'Search' button.

Showing articles 0 to 3 of 3 Filter Applied: risk-benefit assessment (Click to remove) Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies JAMA Neurol 77:184-191, Luna, G.,et al, 2020 Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007 Showing articles 0 to 3 of 3